Feraccru
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Feraccru (ferric trimaltol; Shield Therapeutics/AOP Orphan Pharmaceuticals) is a novel oral ferric iron form with hematinic activity being investigated for the treatment of anemia in chronic kidney disease (CKD). The drug dissociates into ferric iron which is transported to erythroid precursor cells to be incorporated into hemoglobin. Feraccru is awaiting approval in Europe for the treatment of anemia in CKD in inflammatory bowel disease, as an alternative to intravenous iron.
TABLE OF CONTENTS
4 Product Profiles
4 Feraccru : Anemia in chronic kidney disease
LIST OF FIGURES
7 Figure 1: Feraccru for anemia in chronic kidney disease – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Feraccru for anemia in chronic kidney disease
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Feraccru for anemia in chronic kidney disease
11 Figure 4: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
LIST OF TABLES
5 Table 1: Feraccru drug profile
6 Table 2: Feraccru Phase III trials in anemia in chronic kidney disease
12 Table 3: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Mircera 
Sign up to the